Compare SXI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXI | NAMS |
|---|---|---|
| Founded | 1955 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | 1994 | N/A |
| Metric | SXI | NAMS |
|---|---|---|
| Price | $328.07 | $34.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $289.67 | $46.75 |
| AVG Volume (30 Days) | 219.6K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.98 | N/A |
| Revenue | ★ $604,535,000.00 | N/A |
| Revenue This Year | $14.87 | $17.96 |
| Revenue Next Year | $6.07 | $540.65 |
| P/E Ratio | $49.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $152.64 | $20.53 |
| 52 Week High | $363.89 | $42.21 |
| Indicator | SXI | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 60.15 |
| Support Level | $217.86 | $33.83 |
| Resistance Level | N/A | $37.27 |
| Average True Range (ATR) | 15.05 | 1.53 |
| MACD | 1.82 | 0.56 |
| Stochastic Oscillator | 49.47 | 76.74 |
Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.